基于5-脂氧合酶代谢通路的中药复方干预动脉粥样硬化炎症的新思路

A New Idea of Chinese Herbal Compound in the Treatment of Atherosclerotic Inflammation Based on 5-Lipoxygenase Metabolic Pathway

动脉粥样硬化(AS)是一种慢性炎症性病理过程,具有慢性炎症的“共同点”,即炎症消散的缺失和炎症介质的持续释放。抗炎一直是防治AS的有效途径,而促炎症消散则是近年来研究的热点,但很少有兼顾二者研究的报道,主要原因还是炎症介质和促炎症消散介质一般都由不同的信号通路所介导。5-脂氧合酶代谢产物白三烯B_(4)(LTB_(4))和脂氧素(LX)在AS炎症中具有截然相反的作用特点。现系统阐述LTB_(4)和LX在AS炎症中的表达及作用机制,再结合中药复方的多靶点多途径的整合调节作用,从抗炎和促炎症消散两方面干预AS炎症更具有优势,为中药复方干预AS炎症提供一种可能的理论依据和研究新思路。

As a chronic inflammatory disease of blood vessel,atherosclerosis(AS)has a“common ground”of the chronic inflammation.It includes the lack of pro-resolving mediators and the sustained release of inflammatory mediators.Anti-inflammatory is an effective way to prevent AS.And recent studies have found that the absence of inflammation resolution is also an important factor in the formation of AS.However,there are few reports on both studies.The main reason is that inflammatory mediators and pro-resolving mediators are generally mediated by different signal pathways.The 5-lipoxygenase metabolites leukotriene B_(4)(LTB_(4))and lipoxin(LX)have diametrically opposite characteristics in AS inflammation.This paper systematically describes the expression and mechanism of LTB_(4) and LX in AS inflammation,and traditional Chinese medicine compound is more advantageous to intervene in AS inflammation from the aspects of anti-inflammatory and inflammation resolution.It can provide a possible theoretical basis and new ideas for the treatment of AS inflammation with Chinese medicine compound.